Haisco Pharmaceutical Group Co Ltd
SZSE:002653

Watchlist Manager
Haisco Pharmaceutical Group Co Ltd Logo
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
Watchlist
Price: 34.59 CNY -4.45% Market Closed
Market Cap: 38.7B CNY
Have any thoughts about
Haisco Pharmaceutical Group Co Ltd?
Write Note

Haisco Pharmaceutical Group Co Ltd
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Haisco Pharmaceutical Group Co Ltd
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
Operating Expenses
-ÂĄ2.1B
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
-19%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Expenses
-ÂĄ6.4B
CAGR 3-Years
-8%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Expenses
-ÂĄ1.3B
CAGR 3-Years
-5%
CAGR 5-Years
-10%
CAGR 10-Years
-17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Expenses
-ÂĄ16.2B
CAGR 3-Years
4%
CAGR 5-Years
-3%
CAGR 10-Years
-15%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Expenses
-ÂĄ6.5B
CAGR 3-Years
-4%
CAGR 5-Years
-1%
CAGR 10-Years
-12%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Expenses
-ÂĄ1.1B
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Haisco Pharmaceutical Group Co Ltd
Glance View

Market Cap
38.5B CNY
Industry
Pharmaceuticals

Haisco Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products and medical equipment. The company is headquartered in Shannan, Xizang and currently employs 4,247 full-time employees. The company went IPO on 2012-01-17. The Company’s main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The firm distributes its products in domestic market.

Intrinsic Value
21.19 CNY
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Haisco Pharmaceutical Group Co Ltd's Operating Expenses?
Operating Expenses
-2.1B CNY

Based on the financial report for Sep 30, 2024, Haisco Pharmaceutical Group Co Ltd's Operating Expenses amounts to -2.1B CNY.

What is Haisco Pharmaceutical Group Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-19%

Over the last year, the Operating Expenses growth was -6%. The average annual Operating Expenses growth rates for Haisco Pharmaceutical Group Co Ltd have been -6% over the past three years , -1% over the past five years , and -19% over the past ten years .

Back to Top